BLS Pharmaceuticals (FRA:PR80) Tariff Resilience Score: 0/10 (As of Jul. 14, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:PR80 BLS Pharmaceuticals Ltd FRA:PR80
38 GF Score
Price €0.58
GF Value €0.41
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is BLS Pharmaceuticals Tariff Resilience Score?

BLS Pharmaceuticals has the Tariff Resilience Score of 0, which implies that the company might have .

BLS Pharmaceuticals has

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes BLS Pharmaceuticals might have .

BLS Pharmaceuticals  (FRA:PR80) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

BLS Pharmaceuticals Tariff Resilience Score Related Terms

FRA:PR80
38GF Score
BLS Pharmaceuticals Ltd FRA:PR80
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is BLS Pharmaceuticals (FRA:PR80) Overvalued in 2026?

Based on GuruFocus' analysis, BLS Pharmaceuticals stock appears to be overvalued. The current stock price of €0.58 is trading 41% above its estimated GF Value™ of €0.41. GuruFocus considers BLS Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for FRA:PR80:

  • Tariff Resilience Score: 0
  • GF Value™: €0.41 vs. price of €0.58 (41% above fair value)
  • GF Score™: 38/100 with 8 warning signs

No single metric tells the full story. See the FRA:PR80 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BLS Pharmaceuticals Business Description

Comparable Companies
Other Exchanges BLS:Australia
Address 50 Clarence Street, Suite 506, Level 5, Sydney, NSW, AUS, 2000
Bioxyne Ltd is an Australian life science and health products company. The company is engaged in the development, manufacture, and distribution of consumer dietary supplements based on the proprietary probiotic strain of Lactobacillus fermentum PCC. Some of its products include Breathe Life Science, Dr Watson, BLS Clinics, Mirai Solution, CanXChange, and others. The company operates in segments, namely, Pharmaceutical manufacture and wholesale supply (business to business), Manufacture and distribution (wholesale, online, and retail), and Wholesale of patented Probiotics.
38GF Score

Get the complete analysis for FRA:PR80

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.58
Price
€0.41
GF Value